TAMPA, Fla. – Solmaz Sahebjam, M.D., assistant member of the Neuro-Oncology Department and leader of the Phase 1 Clinical Trial Program at Moffitt Cancer Center received the 2018 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). Sahebjam is one of 12 clinical investigators selected to receive the honor, which was announced during the NCI Clinical Trials and Translational Research Advisory Committee meeting held July 11.
The award recognizes and supports outstanding mid-career clinical investigators at NCI-designated cancer centers who are working to improve the lives of people with cancer. Each award recipient is involved in NCI-funded collaborative clinical trials. The award provides partial salary support for two years for the awardee to engage in activities and efforts related to the award.
Solmaz joined Moffitt in 2013, following a Clinical Research Fellowship in Neuro-Oncology and New Drug Development at Princess Margaret Cancer Center, in Toronto. She is the principal investigator of multiple investigator-initiated and pharma-sponsored clinical trials in solid tumors and brain malignancies.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,700 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.